Protein Structure Determination



How are these structures determined?

Why Bother With Structure?

- The amino acid sequence of a protein contains interesting information.
- A protein sequence can be compared to other protein sequences to establish its evolutionary relationship to other proteins and protein families.
- However, for the purposes of understanding protein function, the 3D structure of the protein is far more useful than the sequence.

Protein Sequences Far Outnumber Structures

• Only a small number of protein structures have been experimentally determined.

PDB~64,623 protein structuresGenebank~61,132,599 sequences

• Of the 64,623 structures, only **15,702** are dissimilar in sequence (<30% ID).

Growth of GenBank

Now over 100M sequences and 100B base pairs from 223K species



http://www.ncbi.nlm.nih.gov/Genbank/genbankstats.html

http://www.ncbi.nlm.nih.gov/Sitemap/Summary/statistics.html

Growth of Structural Data



http://www.rcsb.org/pdb/statistics/contentGrowthChart.do?content=total&seqid=100

Growth of Structural Data



http://www.rcsb.org/pdb/statistics/contentGrowthChart.do?content=total&seqid=100

Structural Proteomics

- Use experimentally determined structures to model the structures of similar proteins
 - Threading
 - Homology Modeling
 - Fold recognition

Avoids Ab initio structure determination

- Need representative protein structures for the total repertoire of protein folds
- Provide 3D portraits for all proteins in an organism
- Goal: Use structure to infer function.
 - More sensitive than primary sequence comparisons

Redundancy in PDB (20 April 10)

Sequence identity	Number of non- redundant chains
90%	25615
70%	23116
50%	20306
30%	15702

Unique folds in PDB (SCOP)



Unique topologies in PDB (CATH)



New Topologies and Folds Becoming Rare

Structural Genomics



Initiated in 1999 by NIH Phase I included 9 large centers for high throughput structure determination Phase I ran from ~2000 - 2005

Goal

The long-range goal of the Protein Structure Initiative (PSI) is to make the three-dimensional atomic-level structures of most proteins easily obtainable from knowledge of their corresponding DNA sequences.

http://www.nigms.nih.gov/psi/mission.html

Structural Genomics

Benefits

Structural descriptions will help researchers illuminate structure-function relationships and thus formulate better hypotheses and design better experiments.

The PSI collection of structures will serve as the starting point for structure-based drug development by permitting faster identification of lead compounds and their optimization.

The design of better therapeutics will result from comparisons of the structures of proteins that are from pathogenic and host organisms and from normal and diseased human tissues.

The PSI collection of structures will assist biomedical investigators in research studies of key biophysical and biochemical problems, such as protein folding, evolution, structure prediction, and the organization of protein families and folds.

Technical developments, the availability of reagents and materials, and experimental outcome data in protein production and crystallization will directly benefit all structural biologists and provide valuable assistance to a broad range of biomedical researchers.

Structural Genomics Centers in US PSI-1 Winners

The Joint Center for Structural Genomics (JCSG)

During PSI-2, the JCSG has contributed to the overall goal of maximizing structural coverage of protein families with no structural representation and has continued to developm and disseminate innovative new technologies for structural biology. The JCSG consortium theme is the "central machinery of life" — proteins that are conserved in all kingdoms of life.



The Midwest Center for Structural Genomics (MCSG)

In PSI-2, the multi-institutional consortium is rapidly determining the structures of large numbers of strategically selected proteins using x-ray crystallography both to provide structural coverage of major protein superfamilies and to elucidate the entire protein folding space.



The New York Structural Genomics Research Consortium (NYSGRC)

During PSI-2, the consortium's individual project focuses on new targets, principally protein phosphatases and mul tidomain eukaryotic proteins.



The Northeast Structural Genomics Consortium (NEGS)

In PSI-2, the consortium is solving both prokaryotic and eukaryotic structural representatives from the major domain families constituting the eukaryotic proteome.

RIKEN Structural Genomics/Proteomics Initiative Midwest Center for Structural Genomics Joint Center for Structural Genomics New York SGX Research Center for Structural Gene Northeast Structural Genomics Consortium Structural Genomics Consortium Center for Eukaryotic Structural Genomics TB Structural Genomics Consortium Seattle Structural Genomics Center for Infectious I Center for Structural Genomics of Infectious Diseas Southeast Collaboratory for Structural Genomics Structural Proteomics in Europe Berkeley Structural Genomics Center Montreal-Kingston Bacterial Structural Genomics In Structural Genomics of Pathogenic Protozoa Conso Structure 2 Function Project Ontario Centre for Structural Proteomics Medical Structural Genomics of Pathogenic Protozo Oxford Protein Production Facility Accelerated Technologies Center for Gene to 3D St Mycobacterium Tuberculosis Structural Proteomics Center for Structures of Membrane Proteins Israel Structural Proteomics Center Integrated Center for Structure and Function Inno Marseilles Structural Genomics Program @ AFMB New York Consortium on Membrane Protein Struct Structural Proteomics in Europe 2 Scottish Structural Proteomics Facility Center for High-Throughput Structural Biology New York Structural GenomiX Research Consortium

		lotal Count (not null)): :
	0	2674	4
omics			
Disease			
ses			
nitiative	•		
ortium			
	1		
	1		
ba			
tructure			
Project			
vation			
ture			
n			

Structural Genomics Centers in US PSI-1 Losers

Center for Eukaryotic Structural Genomics (CESG)

The CESG was founded as a collaborative effort to develop the technologies needed for economical high-throughput structure determination of biologically important eukaryotic proteins and to extend the knowledge of fold-function space. This project also aims to further the research of biologically important proteins in Arabidopsis. The protein structures are being determined via X-ray crystallography or NMR spectroscopy.

The Berkeley Structural Genomics Center (BSGC) The BSGC is pursuing an integrated structural genomics program designed to obtain a near-complete structural complement of two minimal genomes, Mycoplasma genitalium and Mycoplasma pneumoniae, two related human and animal pathogens. Both NMR spectroscopy and X-ray crystallography are being used for structural determination.

The Southeast Collaboratory for Structural Genomics (SECSG)

The objective of the SECSG is to develop and test experimental and computational strategies for high throughput structure determination of proteins by X-ray crystallography and NMR methods and to apply these strategies to scan the entire genome of an organism at a rapid pace. The eukaryotic organisms, *Caenorhabditis elegans*, *Homo sapiens* and an ancestrally-related prokaryotic microorganism having a small genome, *Pyrococcus furiosus*, have been selected as representative genomes.

Structural Genomics of Pathogenic Protozoa Consortium (SGPP)

The SGPP consortium aims to determine and analyze the structures of a large number of proteins from major global pathogenic protozoa including *Leishmania major*, *Trypanosoma brucei*, *Trypanosoma cruzi* and *Plasmodium falciparum*. These organisms are responsible for the diseases: leishmaniasis, sleeping sickness, Chagas' disease and malaria. X-ray crystallography is being used for structural determination.

The TB Structural Genomics Consortium (TB)

The goal of the TB consortium is to determine the structures of over 400 proteins from M. tuberculosis, and to analyze these structures in the context of functional information that currently exists and that is generated by the project. These structures will include about 40 novel folds and 200 new families of protein structures. The protein structures are being determined using X-ray crystallography.

Current PSI Centers

Large-Scale Centers

Joint Center for Structural Genomics

Midwest Center for Structural Genomics

New York SGX Research Center for Structural Genomics

Northeast Structural Genomics Consortium

Specialized Centers

Accelerated Technologies Center for Gene to 3D Structure

Center for Eukaryotic Structural Genomics

Center for High-Throughput Structural Biology

Center for Structures of Membrane Proteins

Integrated Center for Structure and Function Innovation

New York Consortium on Membrane Protein Structure

Homology Modeling Centers

Joint Center for Molecular Modeling

New Methods for High-Resolution Comparative Modeling

Resource Centers

PSI-Materials Repository ← PSI Knowledgebase

60,000 plasmid clones

2008 Structural Genomics Progress

Status	Total Number of Targets	(%) Relative to "Cloned" Targets	(%) Relative to ''Expressed'' Targets	(%) Relative to ''Purified'' Targets	(%) Relative to "Crystallized" Targets
Cloned	61522	100.00	-	-	-
Expressed	39540	64.27	100.00	-	-
Soluble	18221	29.62	46.08	-	-
Purified	14031	22.81	35.49	100.00	-
Crystallized	5616	9.13	14.20	40.03	100.00
Diffraction-quality Crystals	2909	4.73	7.36	20.73	51.80
Diffraction	2429	3.95	6.14	17.31	43.25
NMR Assigned	1051	1.71	2.66	7.49	-
HSQC	1890	3.07	4.78	13.47	-
Crystal Structure	2291	3.72	5.79	16.33	40.79
NMR Structure	953	1.55	2.41	6.79	-
In PDB	2849	4.63	7.21	20.31	35.15
Work Stopped	14137	-	-	-	-
Test Target	4	-	-	-	-
Other	10	-	-	-	-

~40% of structures are from SG in Europe and Asia

2010 Structural Genomics Progress

Status	Total Number of Targets	(%) Relative to "Cloned" Targets	(%) Relative to ''Expressed'' Targets	(%) Relative to ''Purified'' Targets	(%) Relative to "Crystallized" Targets
Cloned	176710	100.0	-	-	-
Expressed	123905	70.1	100.0	-	-
Soluble	47572	26.9	38.4	-	-
Purified	43609	24.7	35.2	100.0	-
Crystallized	14641	8.3	11.8	33.6	100.0
Diffraction-quality Crystals	7708	4.4	6.2	17.7	52.6
Diffraction	6628	3.8	5.3	15.2	45.3
NMR Assigned	2154	1.2	1.7	4.9	-
HSQC	3929	2.2	3.2	9.0	-
Crystal Structure	5215	3.0	4.2	12.0	35.6
NMR Structure	2050	1.2	1.7	4.7	-
In PDB	7569	4.3	6.1	17.4	38
Work Stopped	38962	-	-	-	-
Test Target	93	-	-	-	-
Other	8178	-	-	-	-

~36% of structures are from SG in Europe and Asia

http://targetdb.pdb.org/statistics/TargetStatistics.html

Project Attrition



Unique Folds?



Protein Structure Databases

- Where does protein structural information reside?
 - **PDB**:
 - http://www.rcsb.org/pdb/
 - MMDB:
 - http://www.ncbi.nlm.nih.gov/Structure/
 - **FSSP**:
 - http://www.ebi.ac.uk/dali/fssp/
 - SCOP:
 - http://scop.mrc-lmb.cam.ac.uk/scop/
 - CATH:
 - http://www.biochem.ucl.ac.uk/bsm/cath_new/





PDB Contents 20 April 2010

Exp.Method	Proteins	Nucleic Acids	Protein/NA Complexes	Other	Total
X-RAY	52212	1206	2401	17	55836
NMR	7279	896	154	7	8336
ELECTRON MICROSCOPY	195	17	76	0	288
HYBRID	16	1	1	1	19
Other	123	4	4	13	144
Total	59825	2124	2636	38	64623

X-ray Crystallography

Optical Microscope



Atomic Resolution

We want to resolve inter-atomic distances (~1.5 Å, 0.15 nM)

Visible light has a wavelength of $\sim 500 \text{ nm} (5000 \text{ Å})$

Electron beam: $\lambda_c \sim 0.001$ Å (if e⁻ is moving at c) Electron velocity is less in electron microscopes Typical resolution is ~10 Å, but can be improved

X-ray generators produce photons of $\lambda = 0.5 - 2.5$ Å Use $\lambda = 1.542$ Å

X-ray Crystallography **Molecules 3D** electron density map O m a h e **Refocusing is accomplished** m with a computer, a a 0 crystallographer crystallographer computer and a lot of mathematics С S **X-ray detector** Crystal size < 0.5 mm Must use X-rays to get atomic resolution (1.5 \AA = C-C bond) X-rays

X-Ray Crystallography

- Make crystals of your protein

 0.3-1.0mm in size
 Proteins must be in an ordered, repeating pattern.
- 2. X-ray beam is aimed at crystal and data is collected.
- 3. Structure is determined from the diffraction data.

X-Ray Crystallography

- Make crystals of your protein

 0.3-1.0mm in size
 Proteins must be in an ordered, repeating pattern.
- 2. X-ray beam is aimed at crystal and data is collected.
- 3. Structure is determined from the diffraction data.



Schmid, M. Trends in Microbiolgy, **10**:s27-s31.













Water

Precipitant concentration







X-Ray Crystallography

- Make crystals of your protein

 0.3-1.0mm in size
 Proteins must be in an ordered, repeating pattern.
- 2. X-ray beam is aimed at crystal and data is collected.
- 3. Structure is determined from the diffraction data.

X-Ray Diffraction Experiment



Optional: Cryo for protein samples

X-ray Crystallography Equipment



X-ray Crystallography Equipment



X-Ray Crystallography

- Make crystals of your protein

 0.3-1.0mm in size
 Proteins must be in an ordered, repeating pattern.
- 2. X-ray beam is aimed at crystal and data is collected.
- 3. Structure is determined from the diffraction data.

Protein Diffraction Image



Why Spots?

X-ray scattering from individual proteins is diffuse

Spots arise from a phenomenon called diffraction that is based on the crystal lattice

Location of reflections indicates how an object crystallized 230 possibilities

Intensity of reflections contains information about the structure of the object in the crystal

Bragg's Law

Why do we get spots (reflections) and not a diffuse pattern of scattered x-rays?



Difference in path (2x) must equal integral number of wavelengths $(n\lambda)$

Constructive Interference



• Condition for reflection

Resolution



Phase Problem



Every diffraction spot (reflection) has a phase and intensity -The intensities are recorded by the detector

-The phases are lost

-Must have both to reconstruct the image (structure)

Phase Problem



Electron Density

Phase Problem



Solutions to the Phase Problem

Molecular replacement

-Use known structure of close homologue -Rotational and translational search for solution

Heavy atom labeling

-Label the protein with electron dense atoms (Hg)

-Compare independent datasets collected from native and labeled protein

-Heavy atom substructure provides initial phases

Anomalous diffraction

-Crystal must contain atoms with absorption edges between 0.5 and 2.5 Å -Compare independent datasets collected at pre-edu

-Compare independent datasets collected at pre-edge and post-edge x-ray energies

Model Building



Crystallography Pros/Cons

Advantages

- -can be "fast" down to a few months
- -large structures possible (ribosome)
- -very low resolution (down to 0.5 Å)
- -observables typically > refinement parameters

Disadvantages

-requires crystal formation

-non-physiological conditions

-crystal contacts can limit protein motion

Nuclear Magnetic Resonance

Nuclear Magnetic Resonance

Magnetically align unpaired proton spins (H₀)

Probe with radio frequency (RF)

Observe resonance





NMR Overview



Positional refinement typically not possible. Dihedral angles used.

NMR Experimental Observables

- Backbone conformation from chemical shifts (Chemical Shift Index- CSI)
- Distance constraints from NOEs
- Hydrogen bond constraints
- Backbone and side chain dihedral angle constraints from scalar couplings
- Orientation constraints from residual dipolar couplings

NMR Pros/Cons

Advantages

-no crystal formation needed-more physiological conditions

Disadvantages

-results in a set of models that are compatible with data
-size limitation to 200-300 residues (extended recently)
-must label protein with ¹⁵N and ¹³C
-bsorvables typically < refinament parameters

-observables typically < refinement parameters



RMSD of the ensemble

Mean coordinate error

Header contains information about protein and structure date of the entry, references, crystallographic data, contents and positions of secondary structure elements

HEADER OXIDOREDUCTASE 03-OCT-02 1MXT TITLE ATOMIC RESOLUTION STRUCTURE OF CHOLESTEROL OXIDASE TITLE 2 (STREPTOMYCES SP. SA-COO) COMPND MOL_ID: 1; COMPND 2 MOLECULE: CHOLESTEROL OXIDASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CHOD; COMPND 5 EC: 1.1.3.6; COMPND 5 EC: 1.1.3.6; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: FAD COFACTOR NON-COVALENTLY BOUND TO THE COMPND 8 ENZYME

Header contains information about protein and structure date of the entry, references, crystallographic data, contents and positions of secondary structure elements

SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: STREPTOMYCES SP.; SOURCE 3 ORGANISM_COMMON: BACTERIA; SOURCE 4 GENE: CHOA; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_COMMON: BACTERIA; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3)PLYSS; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PCO202

Header contains information about protein and structure date of the entry, references, crystallographic data, contents and positions of secondary structure elements

	AUTHO	R A VRIELINK PI LARIO
	REVDAT	1 25-FEB-03 1MXT 0
	JRNL	AUTH P.I.LARIO, N.SAMPSON, A. VRIELINK
	JRNL	TITL SUB-ATOMIC RESOLUTION CRYSTAL STRUCTURE OF
	JRNL	TITL 2 CHOLESTEROL OXIDASE: WHAT ATOMIC RESOLUTION
	JRNL	TITL 3 CRYSTALLOGRAPHY REVEALS ABOUT ENZYME MECHANISM AND
	JRNL	TITL 4 THE ROLE OF FAD COFACTOR IN REDOX ACTIVITY
<	JRNL	REF J.MOL.BIOL. V. 326 1635 2003
	JRNL	REFN ASTM JMOBAK UK ISSN 0022-2836

Header contains information about protein and structure date of the entry, references, crystallographic data, contents and positions of secondary structure elements

REMARK <u>3 DATA USED IN REFINEMENT.</u>	-
REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS): 0.95	
REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS): 28.00	
REMARK 3 DATA CUTOFF (SIGMA(F)): 0.000	
REMARK 3 COMPLETENESS FOR RANGE (%): 94.1	
REMARK 3 CROSS-VALIDATION METHOD : FREE R	
REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM	
REMARK 3	
REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF).	
REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF): 0.110	R
REMARK 3 R VALUE (WORKING SET, NO CUTOFF): 0.110	
REMARK 3 FREE R VALUE (NO CUTOFF): 0.132	
REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000	
REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF): 13180	
REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF): 263551	

Resolution:

Low > 3 Å Mid 2-3 Å High 1.5-2 Å Very High < 1.5 Å

R factor (residual):

Low resolution ~ 27% Mid resolution ~ 22 % High resolution ~ 29 % Very High res ~ 15%

Resolution

6)

Resolution Dis	stribution - subrange from 0.0 t	o 5.0		
Min: 0.0	Max: 5.0	Mean: 2.18	Std. Deviation: 1.2	
	0			21913
0 - 0.5				
0.5 - 1	1			
1 - 1.5				
1.5 - 2				
2 - 2.5				
2.5 - 3				
3 - 3.5				
3.5 - 4	1			
4 - 4.5	L			
4.5 - 5	L			

Header contains information about protein and structure date of the entry, references, crystallographic data, contents and positions of secondary structure elements

	HELIX	14	14	ALA A	289	THR A	304	1					16
	HELIX	15	15	THR A	402	GLN A	405	5					4
\sim	HELIX	16	16	ASN A	406	GLY A	425	1					20
	HELIX	17	17	ASP A	474	ILE A	478	-5					5
	HELIX	18	18	PRO A	486	VAL A	506	1					21
	SHEET	1	A	6 HIS	A 248	GLN A	4 255	0					
	SHEET	2	А	6 TYR	A 261	LYS /	<u>\ 268</u>	-1	0	<u>GLU A 266</u>	N	<u>GLN A 249</u>	
\frown	SHEET	3	A	6 LEU	A 274	LEU A	A 287	-1	0	leu a 275	Ν	GLN A 267	
	SHEET	4	А	6 TYR	A 10	ILE A	\ 16	-1	N	VAL A 14	0	PHE A 286	
	SHEET	5	A	6 THR	A 36	GLU A	A 40	1	0	LEU A 37	Ν	VAL A 15	
	SHEET	6	A	6 VAL	A 242	THR A	A 246	1	0	THR A 243	N	MET A 38	

Body of PDB file contains information about the atoms in the structure

ATOM	76	Ν	PRO A	12	31.129	-4.659	43.245	1.00	9.00	Ν
ATOM	77	CA	PRO A	12	32.426	-4.662	42.542	1.00	9.00	C
ATOM	78	С	PRO A	12	32.423	-4.009	41.182	1.00	8.02	C
ATOM	79	0	PRO A	12	33.267	-3.177	40.892	1.00	8.31	0
ATOM	80	СВ	PRO A	12	32.791	-6.126	42.592	1.00	10.02	C
ATOM	81	CG	PRO A	12	32.190	-6.663	43.857	1.00	10.12	C
ATOM	82	CD	PRO A	12	30.850	-5.927	43.925	1.00	9.87	C
ATOM	90	Ν	ALA A	13	31.485	-4.468	40.316	1.00	8.06	Ν
ATOM	91	CA	ALA A	13	31.357	-3.854	39.004	1.00	7.28	C
ATOM	92	С	ALA A	13	29.947	-3.309	38.814	1.00	7.21	C
ATOM	93	0	ALA A	13	28.969	-3.932	39.200	1.00	7.56	0
ATOM	94	CB	ALA A	13	31.636	-4.879	37.897	1.00	8.54	C
Atom numb	ber		Res	idue 1	name	Residue	numbe	er		
A	Atom	 1 na	me							

Body of PDB file contains information about the atoms in the structure

ATOM	76	Ν	PRO	А	12
ATOM	77	CA	PRO	А	12
ATOM	78	С	PRO	А	12
ATOM	79	0	PRO	А	12
ATOM	80	СВ	PRO	А	12
ATOM	81	CG	PRO	А	12
ATOM	82	CD	PRO	А	12
ATOM	90	Ν	ALA	А	13
ATOM	91	CA	ALA	А	13
ATOM	92	С	ALA	А	13
ATOM	93	0	ALA	А	13
ATOM	94	СВ	ALA	А	13

Coordinates in Å

31.129	-4.659	43.245	1.00 9.00
32.426	-4.662	42.542	1.00 9.00
32.423	-4.009	41.182	1.00 8.02
33.267	-3.177	40.892	1.00 8.31
32.791	-6.126	42.592	1.00 10.02
32.190	-6.663	43.857	1.00 10.12
30.850	-5.927	43.925	1.00 9.87
31.485	-4.468	40.316	1.00 8.06
31.357	-3.854	39.004	1.00 7.28
29.947	-3.309	38.814	1.00 7.21
28.969	-3.932	39.200	1.00 7.56
31.636	-4.879	37.897	1.00 8.54



Mean coordinate error:

N C C O C C C N C C O C

Low > 3 Å	.4 Å
Mid 2-3 Å	.3 Å
High 1.5-2 Å	.2 Å
Very High < 1.5 Å	.1 Å

Body of PDB file contains information about the atoms in the structure

ATOM	76	Ν	PRO A	12	31.129	-4.659	43.245	1.00	9.00
ATOM	77	CA	PRO A	12	32.426	-4.662	42.542	1.00	9.00
ATOM	78	С	PRO A	12	32.423	-4.009	41.182	1.00	8.02
ATOM	79	0	PRO A	12	33.267	-3.177	40.892	1.00	8.31
ATOM	80	СВ	PRO A	12	32.791	-6.126	42.592	1.00	10.02
ATOM	81	CG	PRO A	12	32.190	-6.663	43.857	1.00	10.12
ATOM	82	CD	PRO A	12	30.850	-5.927	43.925	1.00	9.87
ATOM	90	Ν	ALA A	13	31.485	-4.468	40.316	1.00	8.06
ATOM	91	CA	ALA A	13	31.357	-3.854	39.004	1.00	7.28
ATOM	92	С	ALA A	13	29.947	-3.309	38.814	1.00	7.21
ATOM	93	0	ALA A	13	28.969	-3.932	39.200	1.00	7.56
ATOM	94	СВ	ALA A	13	31.636	-4.879	37.897	1.00	8.54



• Occupancy of 0.5

Fractional occupancy

NCCOCCCNCCOC

Body of PDB file contains information about the atoms in the structure

ATOM	76	Ν	PRO A	12	31.129	-4.659	43.245	1.00	9.00
ATOM	77	CA	PRO A	12	32.426	-4.662	42.542	1.00	9.00
ATOM	78	С	PRO A	12	32.423	-4.009	41.182	1.00	8.02
ATOM	79	0	PRO A	12	33.267	-3.177	40.892	1.00	8.31
ATOM	80	СВ	PRO A	12	32.791	-6.126	42.592	1.00	10.02
ATOM	81	CG	PRO A	12	32.190	-6.663	43.857	1.00	10.12
ATOM	82	CD	PRO A	12	30.850	-5.927	43.925	1.00	9.87
ATOM	90	Ν	ALA A	13	31.485	-4.468	40.316	1.00	8.06
ATOM	91	CA	ALA A	13	31.357	-3.854	39.004	1.00	7.28
ATOM	92	С	ALA A	13	29.947	-3.309	38.814	1.00	7.21
ATOM	93	0	ALA A	13	28.969	-3.932	39.200	1.00	7.56
ATOM	94	СВ	ALA A	13	31.636	-4.879	37.897	1.00	8.54



B-factor Å²

N C C O C C C N C C O C